research use only

AT13148 Akt inhibitor

Cat.No.S7563

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
AT13148 Akt inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 313.78

Jump to

Quality Control

Batch: S756301 DMSO]62 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.87%
99.87

Cell Culture, Treatment & Working Concentration

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
insect cells Function assay 50 mins Inhibition of N-terminal His-tagged full-length human recombinant p70S6K expressed in Spodoptera frugiperda insect cells using AKRRRLSSLRA substrate and and [gamma-33P-ATP] incubated for 50 mins by scintillation counting method, IC50=0.012μM. ChEMBL
U87MG Function assay 1 hr Inhibition of PKB in human U87MG cells assessed as reduction in Gsk3beta Ser9 phosphorylation incubated for 1 hr by time-resolved fluorescence based assay, IC50=1.1μM. ChEMBL
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 62 mg/mL (197.59 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 313.78 Formula

C17H16ClN3O

Storage (From the date of receipt)
CAS No. 1056901-62-2 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles C1=CC(=CC=C1C2=CNN=C2)C(CN)(C3=CC=C(C=C3)Cl)O

Mechanism of Action

Targets/IC50/Ki
PKA
(Cell-free assay)
3 nM
ROCK2
(Cell-free assay)
4 nM
ROCK1
(Cell-free assay)
6 nM
p70S6K
(Cell-free assay)
8 nM
Akt1
(Cell-free assay)
38 nM
Akt3
(Cell-free assay)
50 nM
SGK3
(Cell-free assay)
63 nM
RSK1
(Cell-free assay)
85 nM
Akt2
(Cell-free assay)
402 nM
In vitro
AT13148, as a multi-AGC kinase inhibitor, potently inhibits proliferation with GI50 values of 1.5 to 3.8 μM across a selected panel of cancer cell lines with deregulation of PI3K-AKT-mTOR or RAS-RAF pathways. In PTEN-deficient MES-SA cells, this compound also inhibits AKT and p70S6K signaling.
Kinase Assay
In vitro kinase assays
AT13148 is assayed against 40 kinases and the percentage inhibition at 10 μM of this compound is determined. Individual IC50 values are measured for selected kinases using ATP concentrations equivalent to the Km for each enzyme.
In vivo
AT13148 (50 mg/kg p.o.) markedly inhibits the activity of both AKT and p70S6K AGC kinases, and subsequently exhibits marked antitumor effects in human tumor xenografts.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01585701 Completed
Advanced Solid Tumours
Cancer Research UK
May 2012 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map